Stroke Drug Development Targeting NMDAR

N-methyl-d-aspartate (NMDA)-type glutamate receptors (NMDAR) play an important role in stroke pathogenesis by detecting and processing the conversion of extracellular glutamate signals to various intracellular signals.NMDAR and other ionotropic glutamate receptors induce an influx of calcium ions, leading to calcium-dependent activation of death-signaling proteins downstream of the receptor, triggering a large cascade of signals that synergistically induce neuronal death. Currently, there are two main directions in the development of stroke drugs targeting NMDAR and the GluN2B subunit of NMDAR. Despite decades of research, progress in the development of stroke drugs targeting NMDAR remains slow. Therefore, Ace Therapeutics offers a one-stop research service platform for the development of stroke drugs targeting NMDAR.

Stroke Drug Development Targeting NMDAR


Screening & Validation of NMDAR Antagonists

Given the key role of NMDAR in excitotoxicity, the most straightforward approach is to block NMDAR, and we offer a comprehensive NMDAR antagonist development service for the three main directions in which NMDAR antagonists are currently designed, namely, blocking ion channel pores, blocking glutamate binding sites, and blocking glycine binding sites. The first step is to screen for a large number of antagonists targeting different NMDAR sites and then perform the subsequent pharmacological evaluation of these potential candidate NMDAR antagonists.

For rapid screening of NMDAR antagonists, Ace Therapeutics has established a complete NMDAR antagonist screening process. Combining our ultra-large compound library, natural product library, and fragment library, a large number of NMDAR antagonists are obtained by molecular docking of NMDAR glutamate sites and glycine sites.

To verify the antagonistic effects of candidate NMDAR antagonists on NMDAR, Ace Therapeutics provides abundant cell libraries including African clawed toad oocytes, hippocampal neuronal cells, cortical neuronal cells, and experimental animals such as zebrafish, mice, rats, and non-human primates.

Based on the cell library and abundant experimental animals, Ace Therapeutics has developed a platform for screening NMDAR ion channel antagonists, for rapid screening of ion channel antagonists against NMDAR, and for validating the activity of NMDAR antagonists obtained by molecular docking, including but not limited to

  • Calcium-sensitive fluorescent dye labeling technique
  • Voltage-sensitive fluorescent dye labeling technique
  • Manual membrane clamp system
  • Fully automated membrane clamp system

Preclinical Evaluation of Drug Candidates for the Treatment of Stroke

After screening for NMDAR antagonists, it is very important to test the effect of these drug candidates on stroke recovery. In this regard, we offer different in vitro and in vivo stroke models, and related pharmacokinetic tests, and we also provide appropriate testing services for the above models, including but not limited to

  • NMDAR assay service
  • NMDAR-based electrophysiology detection services
  • NMDAR-based calcium imaging measurement service

Depending on the design of the experiment, we offer personalized and customized services for the development of NMDAR antagonists as stroke drugs. If you would like to learn more about our services, please feel free to contact us.

  1. Goldsmith, P. J. Nmdar pams: Multiple chemotypes for multiple binding sites. Curr Top Med Chem, 2019. 19(24): p. 2239-2253.
  2. Paoletti, P.Neyton, J. Nmda receptor subunits: Function and pharmacology. Curr Opin Pharmacol, 2007. 7(1): p. 39-47.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Inquiry Basket